@article{oai:repo.qst.go.jp:00075677,
 author = {Sudo, Hitomi and Tsuji, Atsushi and Sugyo, Aya and Saga, Tsuneo and K Kaneko, Mika and Kato, Yukinari and Higashi, Tatsuya and Sudo, Hitomi and Tsuji, Atsushi and Sugyo, Aya and Higashi, Tatsuya},
 issue = {5},
 journal = {Cancer Science},
 month = {Feb},
 note = {Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is highly expressed in malignant mesothelioma. The rat-human chimeric antibody NZ-12 has high affinity for human podoplanin and antibody-dependent cellular cytotoxicity, and is applicable for radioimmunotherapy (RIT) to enhance the antitumor effect. In the present study, we evaluated the in vivo and in vitro properties of radiolabeled NZ-12 and the antitumor effect of RIT with  Y-labeled NZ-12 in an NCI-H226 (H226) malignant mesothelioma xenograft mouse model.  In-labeled NZ-12 bound specifically to H226 cells with high affinity, and accumulation was high in H226 tumors but low in major organs. RIT with  Y-labeled NZ-12 significantly suppressed tumor growth and prolonged survival without body weight loss and obvious adverse effects. Higher podoplanin expression levels were observed in human mesothelioma specimens, suggesting higher tumor accumulation of  Y-labeled NZ-12 in patients compared with the H226 tumor xenografts. Our findings suggest that  Y-labeled NZ-12 is a promising RIT agent as a new therapeutic option for malignant mesothelioma that warrants further clinical studies to evaluate the dosimetry and efficacy in patients. This article is protected by copyright. All rights reserved.},
 pages = {1653--1664},
 title = {Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma},
 volume = {110},
 year = {2019}
}